Press Releases

GeneCentric Collaborators from UNC Lineberger Comprehensive Cancer Center Present on Urothelial Cancer at the Genitourinary Cancers Symposium 2019

GeneCentric Therapeutics, Inc. collaborator Dr. Tracy Rose from the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC presented at the Genitourinary Cancers Symposium today on: “Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer.” Through a collaboration announced in December 2018 with UNC Lineberger Comprehensive Cancer Center (UNC-LCCC) and […]

GeneCentric Therapeutics Appoints Michael V. Milburn, PhD, President and Chief Executive Officer

CEO Dr. Myla Lai-Goldman named Executive Chairperson Durham, NC, January 3, 2019 -GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Executive Officer and President and will join GeneCentric’s Board of Directors. Dr. Myla Lai-Goldman, founder, current CEO and President, will assume the newly-created role of Executive Chairperson of the […]

GeneCentric Therapeutics Enters Bladder Cancer Research Collaboration with University of North Carolina

Focus is on advancing cancer subtypes to predict disease progression and pursuing immune-biology related drug response biomarkers DURHAM, N.C., December 10, 2018 — GeneCentric Therapeutics, Inc. today announced that it has entered into a research collaboration with the University of North Carolina at Chapel Hill (UNC) to assess patient response to immunotherapeutic drugs such as […]

GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North Carolina

Company will develop Pancreatic Cancer Profiler based on technology to identify drug responders for therapeutic development DURHAM, N.C., September 24, 2018 — GeneCentric Therapeutics, Inc. today announced that the company has acquired an exclusive license from the University of North Carolina at Chapel Hill (UNC) to technology for subtyping Pancreatic Ductal Adenocarcinoma (PDAC). The company […]

GeneCentric Therapeutics Appoints Michael V. Milburn, PhD, Chief Scientific Officer

GeneCentric Therapeutics, Inc. today announced the appointment of Michael V. Milburn, PhD, as Chief Scientific Officer (CSO).  Dr. Milburn, who joins GeneCentric from Metabolon, Inc. where he was CSO, has more than 25 years of R&D successful leadership experience in biotechnology companies and in a major pharmaceutical company. “Michael brings a broad range of expertise […]

GeneCentric to Present at the Precision Medicine World Conference 2018

GeneCentric Therapeutics’ CEO, Dr. Myla Lai-Goldman, will deliver a presentation at the Precision Medicine World Conference (PMWC) 2018 Duke University Program, September 24-25, entitled: “Delivering Greater Precision to Precision Medicine.” In an interview with PMWC ahead of the conference Dr. Lai-Goldman provides perspectives on novel cancer drug response biomarkers to enable more effective and efficient drug […]

GeneCentric to Co-Chair Panel at the Next Generation Diagnostics Summit 2018

Dr. Myla Lai-Goldman, co-founder and CEO of GeneCentric Therapeutics, will co-Chair a panel at the Next Generation Diagnostics (Dx) Summit 2018, August 20-24 in Washington, DC titled: “Paths to Universal Drug-Diagnostics Co-Development.” Next Generation Diagnostics Summit 2018, in its tenth year, includes over 1,000 international diagnostic professionals working in the field spanning cell- and cell-free […]

GeneCentric Therapeutics to Present First Data on Cancer Subtyping Platform for Bladder Cancer, Potential for Use as Drug Response Biomarker

GeneCentric Therapeutics announced today that it will present the first data on the application of its proprietary Cancer Subtyping Platform (CSP®) to bladder cancer and its potential utility to provide drug response biomarkers for the disease. The gene expression subtyping data will be presented in a poster session at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL on June 2, 2018.

GeneCentric Therapeutics Announces Research Collaboration on Drug Response Biomarkers for Lung Cancer

DURHAM, N.C., January 3, 2018 — GeneCentric Therapeutics, Inc. today announced a research collaboration to evaluate the potential of GeneCentric’s Cancer Subtype Platform (CSP®) to identify responders to G1 Therapeutics’ oral CDK4/6 inhibitor G1T38 for the treatment of non-small cell lung cancer (NSCLC).  As part of the research collaboration, GeneCentric will apply its lung cancer subtyping profilers (LSP™) in preclinical, patient-derived xenograft models to determine NSCLC subtype associations with G1T38 response, as well as examine potential drug response associations with specific genes.

GeneCentric Therapeutics CEO and Founder Dr. Myla-Lai Goldman to be featured on ”Radio In Vivo: Your Link to the Triangle Science Community!” November 1, 2017

Durham, NC, November 1 , 2017 – GeneCentric Therapeutics Founder and CEO, Dr. Myla-Lai Goldman, will be featured today on the radio show ”Radio In Vivo: Your Link to the Triangle Science Community!”, from 11:00am-12:00pm, ET, on WCOM – FM103.5, based in Carrboro, NC.